Diana P. English, MD, a gynecologic oncologist at Stanford Hospital and Clinics, discusses an investigational antibody-drug conjugate (ADC) in ovarian cancer.
Diana P. English, MD
Advertisement
Articles by Diana P. English, MD
Diana P. English, MD, a gynecologic oncologist at Stanford Hospital and Clinics, discusses the development of the antibody drug conjugate (ADC) mirvetuximab soravtansine in ovarian cancer.
Advertisement
Latest Updated Articles
Dr. English on Mirvetuximab Soravtansine in Ovarian CancerPublished: December 20th 2018 | Updated:
Dr. English on an Investigational Antibody-Drug Conjugate in Ovarian CancerPublished: January 25th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
3
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5